77 results about "Acinetobacter baumannii" patented technology

The invention relates to the technical field of antibacterial peptides, and particularly discloses a marine antibacterial peptide and application thereof, and the amino acid sequence of the marine antibacterial peptide is as shown in SEQ ID NO.1: MWKLPKWRNGRRRGFKIPRW. The marine antibacterial peptide CD109 provided by the invention has an inhibition effect on staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa and klebsiella pneumoniae, and has extremely low cytotoxicity.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof in bacteriostasis. Specifically, the preservation number of the plant lactobacillus LP06 is CGMCC (China General Microbiological Culture Collection Center) No. 28412. The plant lactobacillus LP06 provided by the invention can be used for inhibiting the growth of debaryomyces hansenii, candida tropicalis and penicillium rochei, and also has an inhibiting effect on super bacteria acinetobacter baumannii, pseudomonas aeruginosa, klebsiella, escherichia coli, staphylococcus aureus and listeria monocytogenes. The plant lactobacillus LP06 provided by the invention has broad-spectrum bacteriostatic ability, and bacteriostatic powder prepared from the bacterium can be used as a biological preservative for corrosion prevention of dairy products such as yoghourt, cheese and the like and other foods.

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention discloses an antibacterial peptide SAMP4 or a derivative thereof, a pharmaceutical composition and application, and belongs to the technical field of biology, the amino acid sequence of the antibacterial peptide SAMP4 is as shown in SEQ ID NO: 1, and the antibacterial peptide SAMP4 has a broad-spectrum antibacterial effect and can be used for preparing antibacterial peptide SAMP4. The compound has a strong bacteriostatic effect on various gram-positive bacteria such as staphylococcus aureus, enterococcus and streptococcus and various gram-negative bacteria such as escherichia coli, acinetobacter baumannii and pseudomonas aeruginosa, and is strong in antibacterial activity, wide in antibacterial spectrum and low in toxicity. The invention also provides a derivative and a salt of the antibacterial peptide SAMP4 and application of the antibacterial peptide SAMP4 and the derivative and the salt of the antibacterial peptide SAMP4 to research, development and preparation of various antibacterial products or / and antibacterial drugs and treatment of bacterial infectious diseases, and the antibacterial peptide SAMP4 and the derivative and the salt of the antibacterial peptide SAMP4 are remarkable in advantages and wide in application prospect.

The invention discloses an antibacterial peptide and application thereof, and belongs to the technical field of biology. The antibacterial peptide with an inhibition effect on various clinically common pathogenic microorganisms is obtained, and the antibacterial peptide comprises gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, vibrio parahaemolyticus, salmonella gallinarum, salmonella typhimurium and enterobacter sakazakii, and gram-positive bacteria. The antibacterial peptide provided by the invention can be used as an antibacterial peptide, such as staphylococcus aureus, listeria monocytogenes and bacillus cereus, and the antibacterial peptide provided by the invention is novel in structure and easy to prepare.

The invention relates to application of ten antibacterial peptides in the antimicrobial field. The ten antibacterial peptides have strong antibacterial activity on multi-drug-resistant bacteria, including but not limited to gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae and the like, and gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis and the like. Activity research proves that any one of the ten antibacterial peptides has a remarkable effect of inhibiting, killing or preventing microbial infection. Due to the strong antibacterial property of any antibacterial peptide, the antibacterial peptide has wide application potential in the aspects of preparing antibacterial drugs, preservatives, antibacterial coatings, antibacterial fibers, antibacterial packaging materials and the like. Due to the unique property of the antibacterial peptide in the aspect of antibacterial performance, a new direction is provided for the development of efficient and reliable antibacterial agents and antibacterial technologies and products in multiple fields.

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention discloses a polypeptide derived from deep sea microorganisms, and belongs to the technical field of peptide inhibitors. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1; the polypeptide has a bacteriostatic and / or bactericidal function. The polypeptide can inhibit the growth of acinetobacter baumannii at 8 [mu] M and inhibit the growth of escherichia coli and multi-drug-resistant acinetobacter baumannii at 16 [mu] M, and can be used for preparing products with bacteriostatic and / or bactericidal performance, such as food, daily necessities or medical products.

The invention belongs to the field of molecular biological detection, and provides a joint detection composition which is mainly used for detecting related pathogens by using a multiple fluorescent PCR (Polymerase Chain Reaction) analysis method. Therefore, at least four of the klebsiella aerogenes, the stenotrophomonas maltophilia, the streptococcus angina, the acinetobacter baumannii, the klebsiella pneumoniae and the klebsiella oxytoca can be simultaneously detected and distinguished in a single-tube reaction system. Meanwhile, the detection sensitivity of the composition is higher and reaches 500 copies / mL, and the detection is more accurate.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The present invention relates to a composition for preventing or treating gram-negative bacterial infections, the composition comprising T. ni cecropin. According to an aspect of the present invention, the peptide T. ni cecropin has the excellent effects of reducing liver and kidney toxicity values, inflammatory cytokine production, and endotoxins and inhibiting inflammatory cell infiltration in animal models infected with LPS-infected endotoxemia and Carbapenem-resistant Acinetobacter baumannii and can thus be effectively used for preventing or treating bacterial infections (e.g., gram-negative bacterial infections), sepsis, or inflammatory diseases.

The present invention discloses an antimicrobial peptide and its application, wherein the antimicrobial peptide comprises one or more of an antimicrobial peptide PFK having an amino acid sequence as shown in SEQ ID NO: 1, an antimicrobial peptide PVK having an amino acid sequence as shown in SEQ ID NO: 2, and an antimicrobial peptide PIK having an amino acid sequence as shown in SEQ ID NO: 3. The antimicrobial peptides PFK, PVK and PIK of the present invention have antimicrobial effects on Porphyromonas gingivalis, Streptococcus mutans, Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and the antimicrobial peptides PFK, PVK and PIK have low hemolytic activity and low cytotoxicity, and can be used to prepare biological antimicrobial preparations, anti-infective drugs or oral products.

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

The invention discloses a low-temperature denitrification strain and application of the low-temperature denitrification strain. The strain is Acinetobacter Bragg FX1, and the preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) NO: 36583. The strain can efficiently remove ammonia nitrogen, nitrate nitrogen and nitrite nitrogen in water at the temperature of 5-30 DEG C, especially shows the optimal denitrification performance at the temperature of about 10 DEG C, and the removal rate of the ammonia nitrogen and the nitrite nitrogen can reach 99% or above. The strain has strong adaptability to low-temperature environment, can tolerate water quality fluctuation of actual sewage, and solves the problems of low denitrification efficiency and unstable operation caused by insufficient microbial activity of sewage treatment plants in low-temperature regions. The strain can be used for preparing a low-temperature sewage denitrification microbial agent, can be directly added into a low-temperature domestic sewage or industrial wastewater treatment system, does not need to depend on high-energy-consumption heating and heat preservation measures, and has remarkable energy-saving and consumption-reducing potential, good environmental adaptability and wide application prospects.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The application discloses a chimeric endolysin Lys009-Lys009CBD and engineering and application thereof, and belongs to the field of genetic engineering and protein engineering. The application constructs a chimeric endolysin Lys009-Lys009CBD with high activity, and the peptidoglycan hydrolysis activity of the chimeric endolysin Lys009-Lys009CBD on Pseudomonas aeruginosa is 5.30 times that of natural endolysin Lys009 and 27.98 times that of hen egg white lysozyme HEWL. A transmembrane peptide P81417 is further fused to perform transmembrane modification, and an engineering endolysin P81417-Lys009-Lys009CBD is obtained. The engineering endolysin can efficiently lyse Pseudomonas aeruginosa, Acinetobacter baumannii and the like, and has excellent thermal stability. The application enriches the resource library of high-activity endolysins, provides important experimental basis and technical support for developing an anti-drug-resistant bacteria treatment strategy, and also provides a new selection for clinical treatment of multiple drug-resistant bacteria infection.

The application discloses a strain of Acinetobacter, the strain name is C16ZT1, and simultaneously proposes a bacterial agent containing the different bacillus, and further uses the bacterial agent for treating petroleum pollution wastewater. The Acinetobacter can efficiently degrade the petroleum production wastewater containing chain alkanes, can still realize the degradation effect quickly and stably under the conditions of high concentration, high salt and extreme acid and alkali, and can degrade more than 95% of the petroleum production wastewater within 144 hours. In the application in sewage treatment, the strain has strong tolerance, can tolerate high-concentration alkanes, and has a wide adaptation range to salt concentration, pH and the like, and has a good application prospect.

The application belongs to the technical field of medicine, and discloses application of pyruvic acid in preparation of a preparation for improving sensitivity of pathogenic bacteria to antibiotics. Researches of the application show that pyruvic acid can significantly improve the sensitivity of pathogenic bacteria to antibiotics, and pyruvic acid combined with antibiotics can be used to prepare a medicine for treating pathogenic bacterial infection. The medicine has good antibacterial, anti-drug-resistant bacterial and anti-infection effects on pathogenic bacteria such as pseudomonas aeruginosa, acinetobacter baumannii and parahemolytic vibrio, especially drug-resistant bacteria. The medicine has good application value and significance in the production and development of antibacterial drugs and anti-infection drugs in combination with antibiotics.

The application discloses a kind of anti-saline-alkali microbial inoculants and preparation method thereof, belong to the field of microbial technology.The microbial inoculants is made of composite microbial inoculants 100-150 parts, fish bone hydrolysate 10-30 parts, nano silicon sol 1-3 parts.The composite microbial inoculants is made of Trichoderma reesei, Pseudomonas plecoglossicida, Acinetobacter baumannii.The anti-saline-alkali microbial inoculants has remarkable effect on saline-alkali soil improvement, greatly reduces soil acidity, salt content and bulk density, and the yield of saline-alkali soil wheat planting is obviously improved.The soil organic matter content and soil enzyme activity are significantly improved after use, the soil quality and rhizosphere microecological environment are improved, and the enzyme activity in wheat is improved, the stress resistance is improved, the yield reduction caused by saline-alkali stress is reduced, and the use of microbial inoculants can also reduce the amount of chemical fertilizer and pesticide, reduce production cost, and further improve the economic benefit of wheat planting.

The invention belongs to the technical field of bioengineering, and particularly relates to a phage cocktail and application thereof. The bacteriophage cocktail comprises five bacteriophages PGPA20, PGPA60, PAB26, Lkpp-25 and Lkpp-36 which are separated from the natural world, and the bacteriophage cocktail has relatively strong bactericidal activity on pseudomonas aeruginosa, acinetobacter baumannii and K1 / K2 type klebsiella pneumoniae, and has specificity on the pseudomonas aeruginosa, the acinetobacter baumannii and the K1 / K2 type klebsiella pneumoniae; the bacteriophage can be compounded with other substances for use, and a safe and non-toxic bacteriophage killing product is provided for in-vivo and in-vitro infection treatment of pseudomonas aeruginosa, acinetobacter baumannii and K1 / K2 type klebsiella pneumoniae and disinfection and purification of pseudomonas aeruginosa, acinetobacter baumannii and K1 / K2 type klebsiella pneumoniae in the breeding industry and other environments.

The present application provides an antimicrobial peptide of Polysiphonium lanuginosa and its application in the preparation of an anti-infective drug, wherein the amino acid sequence of the antimicrobial peptide of Polysiphonium lanuginosa is SEQ ID NO.1 or SEQ ID NO.2. The antimicrobial peptide of Polysiphonium lanuginosa of the present application has a good antimicrobial effect on a variety of pathogens and drug-resistant pathogens including Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa, and has low cytotoxicity.

The invention discloses a boric acid fused ring derivative as well as a pharmaceutical composition and application thereof. The invention provides a compound as shown in a formula I or a formula II, a deuterated substance of the compound, or a pharmaceutically acceptable salt of the compound. The compound disclosed by the invention has an inhibition effect on serine beta-lactamase (SBLs) and / or metal beta-lactamase (MBLs), and further, the compound disclosed by the invention is combined with beta-lactam antibiotics, so that the compound has relatively high inhibition activity on carbapenem drug-resistant acinetobacter baumannii (CRAB), and is used for treating bacterial infection.

The present invention relates to the technical field of traditional Chinese medicine, and in particular to an antibacterial Chinese medicine composition and its application. The Chinese medicine composition of the present invention includes 1-10 parts of sappan wood extract, 1-3 parts of sanguisorba officinalis charcoal extract, 1-10 parts of rose extract, 1-5 parts of blood-seeing shrew extract, 1-5 parts of madder charcoal extract, 1-5 parts of hawthorn extract, and 1-5 parts of stir-fried tribulus extract. The Chinese medicine composition has a very significant inhibitory effect on Acinetobacter baumannii, and can play a synergistic effect with antibiotics such as imipenem and minocycline, significantly improving the therapeutic effect of Acinetobacter baumannii infection.

This invention discloses the application of *Ulva prostrata* extract in the preparation of preventive and therapeutic antibacterial drugs. The antibacterial components of *Ulva prostrata* are extracted by ethanol extraction using a reflux extraction method. The extract shows significant antibacterial effects against *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Micrococcus luteus*. The minimum inhibitory concentrations (MICs) are 3.125 mg / mL, 12.5 mg / mL, 6.25 mg / mL, and 3.125 mg / mL, respectively. The extract exhibits good stability to heat treatment and ultraviolet light, and shows good antibacterial effects in neutral and slightly alkaline environments. Metal ions affect the antibacterial effect of the extract, but the diameter of the inhibition zone is greater than 7 mm.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

The invention belongs to the technical field of microorganisms, and in particular relates to an Acinetobacter solani BP2 strain and a related application of the Acinetobacter solani BP2 strain. The strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on December 4, 2025, the address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, West Beichen Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.36892. The acinetobacter soilis BP2 is found to have multiple growth promoting functions of efficiently secreting indoleacetic acid, dissolving insoluble organic phosphorus and inorganic phosphorus, fixing nitrogen and producing siderophores at the same time; when applied to the plant growth process, the seed germination and growth of crops can be remarkably promoted. According to the invention, excellent strain resources are provided for soil nutrient activation and plant growth promotion, and a foundation is laid for development of efficient microbial agents.

The application discloses application of BMS-833923 and derivatives thereof and a medicine, and belongs to the technical field of antibiotics. The BMS-833923 and the derivatives thereof can be used as colistin adjuvants to jointly inhibit or eliminate gram-negative bacteria, and can also independently inhibit or eliminate gram-positive bacteria. The gram-negative bacteria can include at least one of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pan-drug-resistant strains BAA-1800, BAA-1794 and BAA-1792, and the gram-positive bacteria can include at least one of Staphylococcus aureus and Bacillus subtilis. By taking the BMS-833923 and the derivatives thereof as adjuvants of colistin, the therapeutic index of the colistin can be effectively expanded, and lower, non-toxic doses of the colistin can be used in clinical treatment of effective treatment of drug-resistant bacterial infections.

The present invention relates to the field of antimicrobial peptide application technology, and more specifically to an antimicrobial peptide MA25 with broad-spectrum antimicrobial activity and its applications. The amino acid sequence of the antimicrobial peptide MA25 is shown in SEQ ID NO. 1. The antimicrobial peptide MA25 of the present invention has antimicrobial activity against a variety of bacteria (Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae) and their drug-resistant strains, and has excellent biosafety and physiological stability. It has broad development prospects and can be used in alternative treatments for bacterial infections or in bacteriostatic or bactericidal applications.

The application discloses a new Schumannella species with antibacterial activity and application thereof, and belongs to the technical field of microorganisms. A strain 10F1B-5-1 is identified as a potential new species of Schumannella (Schumannella), and is classified and named as Schumannella sp. The strain 10F1B-5-1 has been preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.1.16698. The Schumannella 10F1B-5-1 provided by the application has effects on gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis) and gram-negative bacteria (Acinetobacter baumannii), provides a strain resource for research and development of new antibiotics, and has good research value and application potential.

The invention discloses a lactobacillus rhamnosus A21174 for inhibiting infection of multiple drug-resistant strains and clostridium difficile and application of the lactobacillus rhamnosus A21174. The lactobacillus rhamnosus A21174 has an obvious inhibiting effect on drug-resistant staphylococcus aureus, pseudomonas aeruginosa, drug-resistant escherichia coli, drug-resistant acinetobacter baumannii and clostridium difficile type strains. Compared with a commercial strain # imgabs0 # lactobacillus rhamnosus, the lactobacillus rhamnosus A21173 disclosed by the invention has a better antibacterial effect on clostridium difficile. The lactobacillus rhamnosus A21174 also shows good effects in in-vivo and in-vitro experiments such as artificial gastrointestinal fluid resistance, cholate resistance, aging resistance, life prolonging, oxidation resistance, cognition improvement and the like, so that the strain can be used as a probiotic agent for preparing a product for regulating intestinal flora, and has a good application prospect. The invention has important significance for preventing and / or treating diseases caused by multidrug-resistant bacterium infection, clostridium difficile and pseudomonas aeruginosa infection.